The effect of Silymarin on VEGF, VEGFR-1 and IL-1α levels in placental cultures of severe preeclamptic women

Kaya,; Başer, Eralp; Kaya, Şennur; Mk, Takal; Şahin, Feride İffet; Kuşçu, Esra; Yanık, Filiz

doi:10.5152/jtgga.2014.81592

Cited by 2 publications

(1 citation statement)

References 47 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar decrease in VEGF and VEGFR levels was found with silymarin in preeclamptic placenta, however the effect was very modest. 227 There is evidence showing that silymarin reduces VEGF expression at the transcription level. 228…”

Section: Introductionmentioning

confidence: 99%

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions

Koltai¹,

Fliegel

2022

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

The flavonoid silymarin extracted from the seeds of Sylibum marianum is a mixture of 6 flavolignan isomers. The 3 more important isomers are silybin (or silibinin), silydianin, and silychristin. Silybin is functionally the most active of these compounds. This group of flavonoids has been extensively studied and they have been used as hepato-protective substances for the mushroom Amanita phalloides intoxication and mainly chronic liver diseases such as alcoholic cirrhosis and nonalcoholic fatty liver. Hepatitis C progression is not, or slightly, modified by silymarin. Recently, it has also been proposed for SARS COVID-19 infection therapy. The biochemical and molecular mechanisms of action of these substances in cancer are subjects of ongoing research. Paradoxically, many of its identified actions such as antioxidant, promoter of ribosomal synthesis, and mitochondrial membrane stabilization, may seem protumoral at first sight, however, silymarin compounds have clear anticancer effects. Some of them are: decreasing migration through multiple targeting, decreasing hypoxia inducible factor-1α expression, inducing apoptosis in some malignant cells, and inhibiting promitotic signaling among others. Interestingly, the antitumoral activity of silymarin compounds is limited to malignant cells while the nonmalignant cells seem not to be affected. Furthermore, there is a long history of silymarin use in human diseases without toxicity after prolonged administration. The ample distribution and easy accessibility to milk thistle—the source of silymarin compounds, its over the counter availability, the fact that it is a weed, some controversial issues regarding bioavailability, and being a nutraceutical rather than a drug, has somehow led medical professionals to view its anticancer effects with skepticism. This is a fundamental reason why it never achieved bedside status in cancer treatment. However, in spite of all the antitumoral effects, silymarin actually has dual effects and in some cases such as pancreatic cancer it can promote stemness. This review deals with recent investigations to elucidate the molecular actions of this flavonoid in cancer, and to consider the possibility of repurposing it. Particular attention is dedicated to silymarin's dual role in cancer and to some controversies of its real effectiveness.

show abstract

Section: Introductionmentioning

confidence: 99%